Loading...
•
Sep 30, 2023
4DMT Q3 2023 Earnings Report
Reported financial results and provided operational highlights for the third quarter of 2023.
Key Takeaways
4DMT reported a net loss of $10.3 million for Q3 2023, compared to a net loss of $25.7 million for Q3 2022. Cash and cash equivalents were approximately $320 million as of September 30, 2023, and the company expects this to fund operations into the first half of 2026.
Advanced 4D-150 development for wet AMD, completing PRISM Phase 2 Dose Expansion enrollment ahead of schedule and enrolling the first patient in the Population Extension cohort.
Received European Medicines Agency’s Priority Medicines (PRIME) designation for 4D-150 for treatment of wet AMD.
Announced positive interim data from 4D-710 Phase 1/2 AEROW clinical trial for cystic fibrosis; update on FDA interaction expected in Q1 2024.
Gained alignment with FDA on plan to lift clinical hold on 4D-310 for Fabry disease cardiomyopathy; interim Phase 1/2 data update expected in Q1 2024.
Revenue by Segment
Forward Guidance
The company anticipates key clinical and regulatory milestones over the next few months.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...